Senseonics Target of Unusually Large Options Trading (NYSE:SENS)

Senseonics Holdings, Inc. (NYSE:SENS) saw unusually large options trading activity on Monday. Traders acquired 4,425 call options on the stock. This is an increase of approximately 63% compared to the typical volume of 2,719 call options.

Insider Transactions at Senseonics

In related news, CFO Frederick T. Sullivan purchased 124,933 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $0.38 per share, with a total value of $47,474.54. Following the completion of the purchase, the chief financial officer now directly owns 2,478,844 shares of the company’s stock, valued at $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Timothy T. Goodnow purchased 315,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were bought at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the purchase, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at $3,506,210.05. The trade was a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Senseonics

A number of hedge funds and other institutional investors have recently bought and sold shares of SENS. First Light Asset Management LLC bought a new position in shares of Senseonics during the fourth quarter worth $3,366,000. Jane Street Group LLC boosted its position in shares of Senseonics by 6,694.1% during the fourth quarter. Jane Street Group LLC now owns 6,118,786 shares of the company’s stock worth $3,203,000 after purchasing an additional 6,028,726 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Senseonics during the fourth quarter worth $720,000. Millennium Management LLC boosted its position in shares of Senseonics by 299.0% during the fourth quarter. Millennium Management LLC now owns 1,088,029 shares of the company’s stock worth $569,000 after purchasing an additional 815,332 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Senseonics by 9.7% during the fourth quarter. Geode Capital Management LLC now owns 6,405,100 shares of the company’s stock worth $3,354,000 after purchasing an additional 566,704 shares in the last quarter. 12.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on SENS. StockNews.com began coverage on shares of Senseonics in a research note on Thursday, December 26th. They set a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and set a $2.00 price target on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Price Performance

Shares of SENS stock opened at $0.87 on Tuesday. Senseonics has a 52-week low of $0.25 and a 52-week high of $1.40. The stock has a market cap of $517.93 million, a PE ratio of -6.69 and a beta of 0.69. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The firm’s 50 day moving average price is $0.84 and its two-hundred day moving average price is $0.53.

Senseonics (NYSE:SENS) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.09). Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. During the same quarter in the prior year, the firm earned ($0.07) earnings per share. As a group, analysts forecast that Senseonics will post -0.14 EPS for the current year.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.